Haematologica
HAEMATOL/2018/199794
Version 3

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study

Marie Luise Hütter-Krönke, Walter Fiedler, Andrea Kündgen, Jürgen Krauter, Marie von Lilienfeld-Toal, Hartmut Döhner, and Richard Schlenk

Disclosures: The AMLSG 08-07 trial was financially supported by Celgene and study medication was provided by Celgene. Marie Luise Huetter-Kroenke: no conflicts of interests Walter Fiedler: advisory boards for Amgen, Pfizer, Novartis, Jazz and ARIAD/Incyte; patents and royalties from Amgen; support for meeting attendance from Amgen, Gilead, GSO, Teva, Daiichi Sankyo and Jazz; and research funding from Amgen and Pfizer. Andrea Kuendgen: research funding by Celgene Marie v. Lilienfeld-Toal: Travel grants and honoraria from Novartis, Gilead, Astellas, MSD, Celgene, Janssen-Cilag and research funding from Gilead and Novartis Juergen Krauter: no conflicts of interests Hartmut Doehner: Consultation: Abbvie, Agios, Amgen, Astellas, Astex Pharmaceuticals, Celator, Celgene, Janssen, Jazz, Novartis, Seattle Genetics, Sunesis Research Support: AROG Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Novartis, Pfizer, Sunesis Richard Schlenk: RFS reports honoraria from Daiichi Sankyo, Novartis, Pfizer, Janssen and AROG, has served in a consulting or advisory role for Daiichi Sankyo, Novartis, and Pfizer, and received research funding from Pfizer, AstraZeneca, PharmaMar and Novartis as well as Deutsche Forschungsgemeinschaft.

Contributions: MLHK and RFS designed the trial protocol, collected and interpreted data and wrote the manuscript. WF, AK, MLT and JK provided patients. HD supervised the trial. All authors gave final approval of manuscript.